Myambutol (Ethambutol Hydrochloride)

Ethambutol Hydrochloride, the active ingredient in Myambutol, is an antitubercular agent presented as a tablet for oral use. It is employed in the treatment of tuberculosis in adults and children as part of combination therapy. GNH USA supplies Myambutol as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ethambutol is an antitubercular drug that interferes with the mycobacterial cell wall synthesis, making it a core component of standard TB regimens.

Tuberculosis: contributes to bacterial killing when used with other first‑line agents. Pulmonary tuberculosis: helps eradicate infection in lung tissue. Extrapulmonary tuberculosis: used for disease sites outside the lungs. Multidrug‑resistant TB (as part of a regimen): added to strengthen combination therapy.

Ethambutol may cause a range of adverse reactions, from mild to severe. Monitoring for visual changes and other symptoms is essential during therapy.

Common Side Effects: - Visual acuity changes: blurred vision or colour discrimination loss. - Optic neuritis: inflammation of the optic nerve causing visual field defects. - Peripheral neuropathy: tingling or numbness in extremities. - Nausea or vomiting. - Skin rash or pruritus. - Elevated liver enzymes.

Serious or Rare Side Effects: - Severe optic neuritis leading to permanent vision loss. - Hypersensitivity reactions such as Stevens‑Johnson syndrome. - Hepatic failure or severe hepatitis. - Acute renal impairment. - Hemolytic anemia. - Severe electrolyte disturbances.

Ethambutol requires careful monitoring and patient counseling to minimize risks.

Renal impairment: dose adjustment may be needed in patients with reduced kidney function. Visual monitoring: baseline and periodic eye examinations are recommended. Hepatic function: assess liver enzymes before and during treatment. Pregnancy: safety category is unknown; use only if benefits outweigh risks. Pediatric use: dosage is weight‑based and requires strict adherence to prescribing information. Store at ambient temperature below 25°C: keep in the original container, protect from moisture.

Ethambutol can interact with several anti‑TB and non‑TB medicines, affecting efficacy or toxicity.

Major Interactions (Avoid): - Isoniazid: increased risk of optic neuritis. - Rifampicin: heightened hepatotoxic potential. - Streptomycin: additive nephrotoxicity.

Moderate Interactions (Monitor Closely): - Pyrazinamide: combined hepatic stress. - Fluoroquinolones: possible additive neurotoxicity. - Antacids containing aluminium or magnesium: may reduce absorption. - Warfarin: monitor INR for potential anticoagulant effect changes.